LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Lista de Ações・Incyte Corp

Incyte Corp

Fechado

SetorSaúde

98.45 0.8

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

97.02

Máximo

99.69

Indicadores-chave
By Trading Economics
Rendimento	4.1M 303M
Vendas	-234M 1.3B
P/E Médio do Setor	13.682 49.8
EPS	1.81
Margem de lucro	23.834
Funcionários	2,844
EBITDA	-47M 367M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+8.22% upside

Dividendos
By Dow Jones
Próximos Ganhos	28 de jul. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	358M 19B
Abertura anterior	97.65
Fecho anterior	98.45

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

59.52 / 62.66 Suporte e Resistência

Incyte Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de mai. de 2026, 23:55 UTC

Ganhos

Review & Preview: Still Going Strong -- Barrons.com

8 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de mai. de 2026, 20:49 UTC

Ganhos

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 de mai. de 2026, 20:25 UTC

Ganhos

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 de mai. de 2026, 19:43 UTC

Ganhos

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 de mai. de 2026, 19:43 UTC

Ganhos

Cencosud 1Q Net $115M

8 de mai. de 2026, 19:20 UTC

Conversa de Mercado

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 de mai. de 2026, 19:18 UTC

Ganhos

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 de mai. de 2026, 19:16 UTC

Ganhos

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 de mai. de 2026, 19:08 UTC

Ganhos

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 de mai. de 2026, 19:05 UTC

Ganhos

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 de mai. de 2026, 19:02 UTC

Conversa de Mercado

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 de mai. de 2026, 18:51 UTC

Ganhos

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 de mai. de 2026, 18:49 UTC

Ganhos

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 de mai. de 2026, 18:41 UTC

Ganhos

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 de mai. de 2026, 17:38 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 de mai. de 2026, 17:14 UTC

Ganhos

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 de mai. de 2026, 17:04 UTC

Conversa de Mercado

Zcash Caps Off Parabolic Week -- Market Talk

8 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de mai. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

8 de mai. de 2026, 15:39 UTC

Conversa de Mercado

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8 de mai. de 2026, 15:39 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 de mai. de 2026, 15:39 UTC

Conversa de Mercado

Canada's Job Market Sees Worst Start in Years -- Market Talk

8 de mai. de 2026, 15:36 UTC

Conversa de Mercado

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8 de mai. de 2026, 15:20 UTC

Conversa de Mercado

'Altcoin Season' Indicator on the Rise -- Market Talk

8 de mai. de 2026, 15:20 UTC

Conversa de Mercado

Ganhos

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8 de mai. de 2026, 15:05 UTC

Conversa de Mercado

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8 de mai. de 2026, 14:42 UTC

Conversa de Mercado

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

8 de mai. de 2026, 14:39 UTC

Conversa de Mercado

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Comparação entre Pares

Variação de preço

Incyte Corp Previsão

Preço-alvo

By TipRanks

8.22% parte superior

Previsão para 12 meses

Média 108.06 USD 8.22%

Máximo 135 USD

Mínimo 75 USD

Com base em 19 analistas de Wall Street que oferecem metas de preço de 12 meses para Incyte Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

19 ratings

Comprar

Manter

Vender

Com base em 19 analistas que deram avaliações de ações para Incyte Corp - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

59.52 / 62.66Suporte e Resistência

Bullish events outweigh bearish events.

All events are bearish.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation